[go: up one dir, main page]

MX2007005525A - Tratamiento terapeutico de resorcion ose acelerada. - Google Patents

Tratamiento terapeutico de resorcion ose acelerada.

Info

Publication number
MX2007005525A
MX2007005525A MX2007005525A MX2007005525A MX2007005525A MX 2007005525 A MX2007005525 A MX 2007005525A MX 2007005525 A MX2007005525 A MX 2007005525A MX 2007005525 A MX2007005525 A MX 2007005525A MX 2007005525 A MX2007005525 A MX 2007005525A
Authority
MX
Mexico
Prior art keywords
bone resorption
accelerated bone
therapeutic treatment
pharmaceutical composition
treatment
Prior art date
Application number
MX2007005525A
Other languages
English (en)
Inventor
Pnina Fishman
Lea Madi
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of MX2007005525A publication Critical patent/MX2007005525A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere al uso de un agonista de receptor de A3 adenosina (agonista de A3AR) para el tratamiento de resorcion osea acelerada, particularmente, resorcion osea inducida por inflamacion. Especificamente, se proporcionan por la presente invencion un metodo y composicion farmaceutica para el tratamiento de la condicion, el agonista de A3AR que se formula como una composicion farmaceutica que se administra a un sujeto que tiene resorcion osea acelerada. La invencion tambien proporcion el uso del agonista de A3AR en la preparacion de la composicion farmaceutica.
MX2007005525A 2004-11-08 2005-11-08 Tratamiento terapeutico de resorcion ose acelerada. MX2007005525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62556404P 2004-11-08 2004-11-08
PCT/IL2005/001166 WO2006048884A1 (en) 2004-11-08 2005-11-08 Therapeutic treatment of accelerated bone resorption

Publications (1)

Publication Number Publication Date
MX2007005525A true MX2007005525A (es) 2007-07-05

Family

ID=36001028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005525A MX2007005525A (es) 2004-11-08 2005-11-08 Tratamiento terapeutico de resorcion ose acelerada.

Country Status (9)

Country Link
EP (1) EP1811982A1 (es)
JP (1) JP2008519029A (es)
KR (1) KR20070085839A (es)
CN (1) CN101072554A (es)
AU (1) AU2005302090A1 (es)
BR (1) BRPI0517639A (es)
CA (1) CA2586845A1 (es)
MX (1) MX2007005525A (es)
WO (1) WO2006048884A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0619395A2 (pt) * 2005-11-30 2011-10-04 Can Fite Biopharma Ltd uso de um agonista de receptor de adenosina a3(a3ar)
DK2137202T3 (en) 2007-03-14 2017-10-02 Can-Fite Biopharma Ltd PROCEDURE FOR SYNTHESIS OF IB-MECA
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
AU2010250759B2 (en) * 2009-05-17 2013-03-14 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5294100A (en) * 1999-05-27 2000-12-18 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US7141553B2 (en) * 2002-11-19 2006-11-28 Can-Fite Biopharma Ltd. Israel A3AR agonists for the treatment of inflammatory arthritis
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
KR20070004792A (ko) * 2004-03-05 2007-01-09 캠브리지 바이오테크놀로지 리미티드 아데노신 수용체 작용제

Also Published As

Publication number Publication date
CN101072554A (zh) 2007-11-14
WO2006048884A1 (en) 2006-05-11
BRPI0517639A (pt) 2008-10-14
KR20070085839A (ko) 2007-08-27
AU2005302090A1 (en) 2006-05-11
CA2586845A1 (en) 2006-05-11
EP1811982A1 (en) 2007-08-01
JP2008519029A (ja) 2008-06-05

Similar Documents

Publication Publication Date Title
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
SG171649A1 (en) Dpp iv inhibitor formulations
EP2114925A4 (en) AZETIDINE ANALOGUE AIS NUCLEOSIDASE AND PHOSPHORYLASE HEMMER
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
TW200633980A (en) Pyridones useful as inhibitors of kinases
MEP27408A (en) Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
TNSN08396A1 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
EA200800162A1 (ru) Новые фармацевтические композиции с замедленным высвобождением и способы их получения
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
MX2009013321A (es) Derivados de espiro[piperidin-4,4'-tieno[3,2-c]pirano] y compuestos relacionados como inhibidores del receptor sigma para el tratamiento de psicosis.
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
TW200611695A (en) Pyrrolopyridine derivatives
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
MX2007005525A (es) Tratamiento terapeutico de resorcion ose acelerada.
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
TW200833710A (en) Treatment for spinal muscular atrophy
TWI256388B (en) Pharmaceutical combination
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
EP1260221A3 (en) Combination treatment for depression and anxiety

Legal Events

Date Code Title Description
FA Abandonment or withdrawal